High co-expression of Sp1 and HER-2 is correlated with poor prognosis of gastric cancer patients

Surgical Oncology

Volumn 24, Issue 3, 2015, Pages 220-225

  Jiang, Weihua ^a,b   Jin, Ziliang ^a,b   Zhou, Fei ^a,b   Cui, Jiujie ^a,b   Wang, Lei ^a,b   Wang, Liwei ^a,b  

^a SHANGHAI JIAO TONG UNIVERSITY   (China)

^b Shanghai Key Laboratory of Pancreas Disease   (China)

Author keywords

Gastric cancer; HER 2; Immunohistochemistry; Prognosis; Sp1

Indexed keywords

CISPLATIN; EPIDERMAL GROWTH FACTOR RECEPTOR 2; FLUOROURACIL; TRANSCRIPTION FACTOR SP1; ERBB2 PROTEIN, HUMAN; SP1 PROTEIN, HUMAN; TUMOR MARKER;

AGED; CANCER COMBINATION CHEMOTHERAPY; CANCER PATIENT; CANCER PROGNOSIS; CANCER TISSUE; CLINICAL FEATURE; CLINICAL PRACTICE; CONTROLLED STUDY; CORRELATIONAL STUDY; DIAGNOSTIC TEST ACCURACY STUDY; FEMALE; FLUORESCENCE IN SITU HYBRIDIZATION; GENE AMPLIFICATION; GENE OVEREXPRESSION; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LONG TERM SURVIVAL; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MALE; PREDICTIVE VALUE; PRIORITY JOURNAL; PROPORTIONAL HAZARDS MODEL; PROTEIN EXPRESSION; RECURRENCE FREE SURVIVAL; REVIEW; RISK FACTOR; SCORING SYSTEM; STOMACH CANCER; STOMACH CARCINOMA; STOMACH SURGERY; SURVIVAL RATE; TUMOR DIFFERENTIATION; TUMOR VOLUME; UNIVARIATE ANALYSIS; ADULT; CANCER STAGING; GENETICS; METABOLISM; MIDDLE AGED; PROGNOSIS; RETROSPECTIVE STUDY; STOMACH NEOPLASMS; TUMOR RECURRENCE; YOUNG ADULT;

ADULT; AGED; BIOMARKERS, TUMOR; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; IN SITU HYBRIDIZATION, FLUORESCENCE; MALE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; NEOPLASM STAGING; PROGNOSIS; RECEPTOR, ERBB-2; RETROSPECTIVE STUDIES; SP1 TRANSCRIPTION FACTOR; STOMACH NEOPLASMS; SURVIVAL RATE; YOUNG ADULT;

EID: 84942197798     PISSN: 09607404     EISSN: 18793320     Source Type: Journal    
DOI: 10.1016/j.suronc.2015.05.004     Document Type: Review

References (19)

1. A. Jemal, F. Bray, M.M. Center, J. Ferlay, E. Ward, and D. Forman Global cancer statistics CA Cancer J. Clin. 61 2 2011 69 90
2. W. Chen, R. Zheng, S. Zhang, P. Zhao, G. Li, L. Wu, and J. He The incidences and mortalities of major cancers in China, 2009 Chin. J. Cancer 32 3 2013 106 112
3. M. Van Ness, J. Gregg, J. Wang, and M. Chen Genetics and molecular pathology of gastric malignancy: development of targeted therapies in the era of personalized medicine J. Gastrointest. Oncol. 3 3 2012 243 251
4. M.C. Hung, and Y.K. Lau Basic science of Her-2: a review Semin. Oncol. 26 1999 51 59
5. N. Hirashima, W. Takahashi, S. Yoshii, T. Yamane, and A. Ooi Protein overexpression and gene amplification of c-erb B-2 in pulmonary carcinomas: a comparative immunohistochemical and fluorescence in situ hybridization study Mod. Pathol. 14 2001 556 562
6. J.S. Ross, C. Sheehan, A.M. Hayner-Buchan, R.A. Ambros, and B.V. Kallakury Kaufman R,Fisher HA, Muraca PJ: Her-2 gene amplification status in prostate cancer by fluorescence in situ hybridization Hum. Pathol. 28 1997 827 833
7. S. Kaptain, L.K. Tan, and B. Chen Her-2 and breast cancer Diagn Mol. Pathol. 10 2001 139 152
8. D.I. Park, J.W. Yun, J.H. Park, and et al. Her-2 amplification is an independent prognosticactor in gastric cancer Dig. Dis. Sci. 51 2006 1371 1379
9. C. Chen, J.M. Yang, T.T. Hu, and et al. Prognostic role of human epidermal growth factor receptor in gastric cancer: a systematic review and meta-analysis Arch. Med. Res. 44 2013 380 389
10. M.E. Fernandez-Zapico, G.A. Lomberk, S. Tsuji, and et al. A functional family-wide screening of Sp/KLF proteins identifies a subset of suppressors of KRAS-mediated cell growth Biochem. J. 435 2011 529 537
11. L. Wang, D. Wei, K. Xie, and et al. Transcription factor Sp1 expression is a significant predictor of survival in human gastric cancer Clin. Cancer Res. 9 17 2003 6371 6380
12. Y.J. Bang, E. van Cutsem, A. Feyereislova, and et al. ToGA Trial Investigators: Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3,open-label, randomised controlled trial Lancet 376 2010 687 697
13. M. Hofmann, O. Stoss, D. Shi, and et al. Assessment of a HER2 scoring system for gastric cancer: results from a validation study Histopathology 52 2008 797 805
14. B.G. Jang, and W.H. Kim Molecular pathology of gastric carcinoma Pathobiology 78 6 2011 302 310
15. K.1 Beishline, and J. Azizkhan-Clifford Sp1 and the 'hallmarks of cancer' FEBS J. 282 2 2015 224 258
16. Chen Y, Gill GN. Positive and negative regulatory elements in the human erbB-2 gene promoter. Oncogene.9(8):2269-2276.
17. S. Ishii, F. Imamoto, Y. Yamanashi, and et al. Characterization of the promoter region of the human c-erbB-2 protooncogene Proc. Natl. Acad. Sci. U. S. A. 84 13 1987 4374 4378
18. M.C. Hsu, H.C. Chang, and W.C. Hung Her-2 represses the metastasis suppressor RECK via ERK and Sp transcription factors to promote cell invasion J. Biol. Chem. 281 8 2006 4718 4725
19. F. Zhou, N. Li, L. Wang, and et al. Prognosis significance of Her-2 overexpression/amplification in Chinese patients with curatively resected gastric cancer after the ToGA clinical trial World J. Surg. Oncol. 10 2012 274